Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

被引：11

作者：

Tettero, Jesse M. ^{[1
,2
]}

Ngai, Lok Lam ^{[1
,2
]}

Bachas, Costa ^{[1
,2
]}

Breems, Dimitri A. ^{[3
]}

Fischer, Thomas ^{[4
]}

Gjertsen, Bjorn T. ^{[5
]}

Gradowska, Patrycja ^{[6
]}

Griskevicius, Laimonas ^{[7
,8
]}

Janssen, Jeroen J. W. M. ^{[1
,2
]}

Juliusson, Gunnar ^{[9
]}

Maertens, Johan ^{[10
]}

Manz, Markus G. ^{[11
]}

Pabst, Thomas ^{[12
,13
,14
]}

Passweg, Jakob ^{[12
,14
]}

Porkka, Kimmo ^{[15
]}

Valk, Peter J. M. ^{[16
,17
]}

Loewenberg, Bob ^{[16
,17
]}

Ossenkoppele, Gert J. ^{[1
,2
]}

Cloos, Jacqueline ^{[1
,2
]}

机构：

[1] Univ Amsterdam, Locat VUmc, Med Ctr, Amsterdam, Netherlands

[2] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands

[3] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium

[4] Otto von Guericke Univ Hosp Magdeburg, Magdeburg, Germany

[5] Haukeland Hosp, Bergen, Norway

[6] Erasmus MC Canc Inst, Data Ctr, Dutch Belgian Hemato Oncol Cooperat Grp, Rotterdam, Netherlands

[7] Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania

[8] Vilnius Univ, Vilnius, Lithuania

[9] Skanes Univ Hosp, Lund, Sweden

[10] Univ Hosp Gasthuisberg, Leuven, Belgium

[11] Univ Hosp, Zurich, Switzerland

[12] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland

[13] Inselspital Bern, Dept Med Oncol, Bern, Switzerland

[14] Univ Hosp, Basel, Switzerland

[15] Helsinki Univ Hosp, Canc Ctr, Helsinki, Finland

[16] Erasmus Univ, Med Ctr MC, Rotterdam, Netherlands

[17] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

HAEMATOLOGICA | 2023年 / 108卷 / 10期

关键词：

ADULTS; AML; YOUNGER;

D O I：

10.3324/haematol.2022.282639

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2794 / 2798

页数：5

共 50 条

[1] Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Yu, Sijian
Fan, Zhiping
Ma, Liping
Wang, Yu
Huang, Fen
Zhang, Qing
Huang, Jiafu
Wang, Shunqing
Xu, Na
Xuan, Li
Xiong, Mujun
Han, Lijie
Sun, Zhiqiang
Zhang, Hongyu
Liu, Hui
Yu, Guopan
Shi, Pengcheng
Xu, Jun
Wu, Meiqing
Guo, Ziwen
Xiong, Yiying
Duan, Chongyang
Sun, Jing
Liu, Qifa
Zhang, Yu
JAMA NETWORK OPEN, 2021, 4 (07)
[2] Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?
Swaminathan, Mahesh
Ravandi, Farhad
HAEMATOLOGICA, 2023, 108 (10) : 2561 - 2563
[3] Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Pan, Jonathan
Altman, Daniel
Wilde, Lindsay
FRONTIERS IN ONCOLOGY, 2020, 10
[4] Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia
Wong, Zoe C.
Dillon, Laura W.
Hourigan, Christopher S.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2023, 36 (02)
[5] Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
Gutman, Jonathan A.
Winters, Amanda
Kent, Andrew
Amaya, Maria
Mcmahon, Christine
Smith, Clayton
Jordan, Craig T.
Stevens, Brett
Minhajuddin, Mohammad
Pei, Shanshan
Schowinsky, Jeffrey
Tobin, Jennifer
O'Brien, Kelly
Falco, Angela
Taylor, Elizabeth
Brecl, Constance
Zhou, Katie
Ho, Phuong
Sohalski, Connor
Dell-Martin, Jessica
Ondracek, Olivia
Abbott, Diana
Pollyea, Daniel A.
HAEMATOLOGICA, 2023, 108 (10) : 2616 - 2625
[6] Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1
Han, Lijie
Li, Yilu
Wu, Jiaying
Peng, Jie
Han, Xiaolin
Zhao, Hongmian
He, Chen
Li, Yuanyuan
Wang, Weimin
Zhang, Mengmeng
Li, Yafei
Sun, Hui
Cao, Haixia
Sang, Li'na
Jiang, Zhongxing
Yu, Jifeng
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (06) : 892 - 901
[7] Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia A Randomized Clinical Trial
Bornhaeuser, Martin
Schliemann, Christoph
Schetelig, Johannes
Roellig, Christoph
Kramer, Michael
Glass, Bertram
Platzbecker, Uwe
Burchert, Andreas
Haenel, Mathias
Mueller, Lutz P.
Klein, Stefan
Bug, Gesine
Beelen, Dietrich
Roesler, Wolf
Schaefer-Eckart, Kerstin
Schmid, Christoph
Jost, Edgar
Lenz, Georg
Tischer, Johanna
Spiekermann, Karsten
Pfirrmann, Markus
Serve, Hubert
Stoelzel, Friedrich
Alakel, Nael
Middeke, Jan Moritz
Thiede, Christian
Ehninger, Gerhard
Berdel, Wolfgang E.
Stelljes, Matthias
JAMA ONCOLOGY, 2023, 9 (04) : 519 - 526
[8] Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia
Stock, Claudia Nunez-Torron
Chillon, Carlos Jimenez
Moro, Fernando Martin
Palomanes, Juan Marquet
Villaespesa, Miguel Piris
Santiago, Ernesto Roldan
Martin, Eulalia Rodriguez
Rodriguez, Anabelle Chinea
Gutierrez, Valentin Garcia
Jimenez, Gemma Moreno
Jimenez, Javier Lopez
Puente, Pilar Herrera
FRONTIERS IN ONCOLOGY, 2024, 14
[9] Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy
Appelbaum, Frederick R.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (04) : 405 - 409
[10] Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60years
Zhang, Ying
Zhang, Yimin
Chen, Qi
Tang, Gusheng
Zhang, Weiping
Yang, Jianmin
Wang, Jianmin
Hu, Xiaoxia
ANNALS OF HEMATOLOGY, 2019, 98 (04) : 997 - 1007

← 1 2 3 4 5 →